e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 20, 2010
Cytokinetics, Incorporated
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50633
|
|
94-3291317 |
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.) |
|
|
|
280 East Grand Avenue, South San Francisco,
California
|
|
94080 |
|
|
|
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code:(650) 624 3000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 5.07. Submission of Matters to a Vote of Security Holders.
On May 20, 2010, Cytokinetics, Inc. (the Company) held its Annual Meeting of
Stockholders in South San Francisco, California. Of the 62,464,802 shares of the Companys common
stock entitled to vote at the meeting, 53,790,766 shares of common stock, or 86.11%, of the total
eligible votes to be cast, were represented at the meeting in person or by proxy, constituting a
quorum. The final results of voting for each matter submitted to a vote of stockholders at the
meeting were as follows:
Proposal 1: Election of Directors
The stockholders elected Stephen Dow, John T. Henderson and Michael Schmertzler as Class III
directors, each to serve for a three-year term and until their successors are duly elected and
qualified. The voting for each director was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Name |
|
For |
|
|
Withheld |
|
|
Broker Non-Vote |
|
Stephen Dow |
|
|
44,204,604 |
|
|
|
303,937 |
|
|
|
9,282,225 |
|
John T. Henderson |
|
|
44,165,556 |
|
|
|
342,985 |
|
|
|
9,282,225 |
|
Michael Schmertzler |
|
|
42,878,496 |
|
|
|
1,630,045 |
|
|
|
9,282,225 |
|
Proposal 2: Ratification of Independent Registered Public Accounting Firm
The stockholders ratified the selection by the Audit Committee of the Board of Directors
of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2010. The votes were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Vote |
53,575,238 |
|
|
143,987 |
|
|
|
71,541 |
|
|
|
0 |
|
|
Proposal 3: Approval of an Amendment to the Companys 2004 Equity Incentive Plan |
|
|
The
stockholders approved an amendment to the 2004 Equity Incentive Plan,
as amended, to increase the
number of authorized shares reserved for issuance thereunder by 2,300,000 shares. The votes were as
follows: |
|
For |
|
Against |
|
Abstain |
|
Broker Non-Vote |
37,691,035 |
|
|
4,498,757 |
|
|
|
2,318,749 |
|
|
|
9,282,225 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Cytokinetics, Incorporated
|
|
May 24, 2010 |
By: |
/s/ Sharon A. Barbari
|
|
|
|
Name: |
Sharon A. Barbari |
|
|
|
Title: |
Executive Vice President, Finance and Chief Financial Officer |
|
|